ProShares Ultra Nasdaq Biotechnology Rating $106.89 -0.70 (-0.65%) Closing price 03:52 PM EasternExtended Trading$106.92 +0.02 (+0.02%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsSEC FilingsTrendsBuy This Stock ProShares Ultra Nasdaq Biotechnology Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BIB Aggregate RatingModerate Buy 2.69Holdings in BIB have an aggregate rating of Moderate Buy based on 397 analyst ratings issued in the past year covering 19 companies (29.5% of the portfolio).BIB Aggregate Price Target$106.89High Prediction$106.89Average Prediction$106.89Low Prediction$106.89Holdings in BIB have an aggregate price target of $106.89 and a range of $106.89 to $106.89 covering 19 companies (29.5% of the portfolio).BIB Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy2 Buy rating(s)Moderate Buy12 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by ProShares Ultra Nasdaq Biotechnology Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 19 BIB Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings4.65%AMGNAmgen$415.21-0.6%3.8123 of 5 stars2.35$372.39 -10.3%31Analyst ForecastInsider Trade4.23%VRTXVertex Pharmaceuticals$505.75-2.1%4.4256 of 5 stars2.92$563.50 11.4%243.78%GILDGilead Sciences$138.36+0.2%4.4449 of 5 stars2.83$158.04 14.2%29Trending NewsAnalyst DowngradeOptions VolumeAnalyst Revision2.94%REGNRegeneron Pharmaceuticals$803.48-0.3%3.7808 of 5 stars2.62$793.74 -1.2%26Insider Trade1.59%RVMDRevolution Medicines$203.71+0.8%2.4241 of 5 stars2.91$161.79 -20.6%22Analyst Forecast1.12%BIIBBiogen$209.83-0.4%4.0032 of 5 stars2.58$227.07 8.2%33Analyst Downgrade1.06%ALNYAlnylam Pharmaceuticals$228.65+0.7%4.8293 of 5 stars2.92$393.86 72.3%24Analyst Forecast1.03%ILMNIllumina$190.89-0.9%3.2259 of 5 stars2.47$188.40 -1.3%17Positive News1.03%INSMInsmed$123.74-2.1%3.3444 of 5 stars3.00$205.52 66.1%26Insider TradeAnalyst Revision0.95%ROIVRoivant Sciences$36.20-0.2%1.61 of 5 stars2.83$35.14 -2.9%12Positive News0.92%RPRXRoyalty Pharma$58.60+0.1%4.3677 of 5 stars3.00$60.86 3.9%8Analyst Forecast0.88%INCYIncyte$120.16-0.3%3.5373 of 5 stars2.43$120.65 0.4%23Analyst Forecast0.87%ARGXargenex$851.29-0.7%4.7633 of 5 stars2.92$1,056.89 24.2%24Positive News0.85%MRNAModerna$63.32-0.5%1.3518 of 5 stars1.88$42.13 -33.5%170.83%UTHRUnited Therapeutics$499.73-0.3%4.355 of 5 stars2.85$646.00 29.3%13Insider TradeAnalyst Revision0.81%GHGuardant Health$157.21-1.5%3.2527 of 5 stars2.96$183.78 16.9%25Insider Trade0.70%VTRSViatris$16.23+1.2%2.5827 of 5 stars2.57$17.50 7.8%7Positive News0.61%MEDPMedpace$578.50-0.6%3.5613 of 5 stars2.23$584.18 1.0%13Analyst UpgradeInsider Trade0.60%BBIOBridgeBio Pharma$79.86-1.7%3.5414 of 5 stars2.83$100.79 26.2%23Trending NewsEarnings ReportAnalyst Forecast This page (NASDAQ:BIB) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredOne wafer-scale chip does in minutes what AI takes daysNVIDIA has dominated the AI computing race, but history shows even titans can be dethroned, just ask IBM. T...Eagle Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares Ultra Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share ProShares Ultra Nasdaq Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
